Cue Biopharma
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
40 Guest St, Boston, Massachusetts, 0213...Phone Number
(617) 949-2680Website
www.cuebiopharma.comRevenue
$32.7 MillionStock Symbol
CUEIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cue Biopharma
Cue Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutic biologics designed to selectively engage and modulate disease-relevant immune cells. The company is dedicated to advancing treatments for immunological disorders, including allergic and autoimmune diseases, with the goal of enabling functional cures and improving patient outcomes. Its research and development efforts are centered on leveraging the body's natural immune mechanisms through precision-targeted therapies that address underlying disease processes while minimizing the risks associated with broad immune system modulation.Explore more
Cue Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cue Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Cue Biopharma has new funding data
Check out if Cue Biopharma is spiking on competitors!
Check if Cue Biopharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cue Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Cue Biopharma launches new products
Earning: See what the market has to say on Cue Biopharma recently announced quarterly report
Click to see if Cue Biopharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Cue Biopharma
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cue Biopharma
Compare insights from companies similar to Cue Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cue Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cue Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cue Biopharma.
Cue Biopharma financials insights
Gather financial insights about Cue Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Stock Offering
$66.2M
2022
Other Financing Round
$30M
2026
Stock/Share Issuance
$30M
Stock/Share Issuance
$50M
Cue Biopharma Tech Stack
A closer look at the technologies used by Cue Biopharma
Most Recent Scoops
Funding
Funding
Person-Based
Events, Intellectual Property, Legal Affairs
Project
Cue Biopharma has announced that CUE-221, its novel anti-IgE therapy, is engineered with a dual mechanism of action that both neutralizes free IgE with high potency and down-regulates new IgE production, a combination designed to deliver deeper and more durable disease control across multiple allergic diseases.
Project
Cue Biopharma has announced CUE-401, a first-in-class bifunctional cytokine designed to target both IL-2 and TGF-β signaling within a single molecule to harness regulatory T cell function, which is advancing toward Phase I clinical development in autoimmune disease.
Partnership
Partnership
Cue Biopharma News & Media
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergy Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergyCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseasesCue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle
Cue Biopharma announced a private placement expected to close on July 13, 2026, raising approximately $50.0 million to support clinical development and general corporate purposes. Under a Securities Purchase Agreement, investors will acquire 1,418,071 common shares at $33.21 per share and pre-funde…
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Cue Biopharma
Sign Up For FreeTo access detailed company insights
Cue Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutic biologics designed to selectively engage and modulate disease-relevant immune cells. The company is dedicated to advancing treatments for immunological disorders, including allergic and autoimmune diseases, with the goal of... Read More
